RKI-1447
RKI-1447 is a small molecule inhibitor of Rho-associated protein kinase (ROCK), a serine/threonine-specific protein kinase that is involved in the regulation of the shape and movement of cells. RKI-1447 was developed by researchers at the Rutgers Cancer Institute of New Jersey and is currently being studied for its potential use in the treatment of cancer and other diseases.
Mechanism of Action
RKI-1447 works by inhibiting the activity of ROCK, which is involved in the formation of stress fibers and focal adhesions, structures that are important for cell movement. By inhibiting ROCK, RKI-1447 can prevent the formation of these structures and thus inhibit cell movement. This can be particularly useful in the treatment of cancer, as it can prevent cancer cells from spreading to other parts of the body, a process known as metastasis.
Potential Therapeutic Applications
The primary potential therapeutic application of RKI-1447 is in the treatment of cancer. In preclinical studies, RKI-1447 has been shown to inhibit the growth and spread of several types of cancer cells, including breast cancer cells, lung cancer cells, and melanoma cells. In addition to its potential use in cancer treatment, RKI-1447 may also have applications in the treatment of other diseases that involve abnormal cell movement, such as atherosclerosis and rheumatoid arthritis.
Clinical Trials
As of now, RKI-1447 is still in the preclinical stage of development, and has not yet been tested in humans. However, the results of preclinical studies have been promising, and it is hoped that clinical trials will be able to begin in the near future.
Safety and Side Effects
The safety and side effects of RKI-1447 are not yet known, as it has not yet been tested in humans. However, in preclinical studies, it has been shown to be well-tolerated in animals.
See Also
- Rho-associated protein kinase
- Cancer
- Metastasis
- Breast cancer
- Lung cancer
- Melanoma
- Atherosclerosis
- Rheumatoid arthritis
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD